Loading data for BNTC — first visit, this takes a few seconds.

Alerta

Benitec Biopharma Inc. (BNTC)

NasdaqCM: BNTC · Precio en tiempo real · USD

12.54

+0.20 (1.62%)

Al cierre: Aug 19, 2026, 3:59 PM

1.62% (1D)

Precio de compra	8.9
Capitalización de mercado	459.66M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-41.54M
Beta	0.26
EPS (TTM)	-0.96
Ratio PER (TTM)	n/a
Adelante PE	-1.42
P/B (TTM)	2.51
P/S (TTM)	n/a
Earnings Date	Sep 22, 2026

Precio de venta	16.01
Volumen	6,000
Volumen medio (20D)	124,382
Abierto	12.40
Anterior Cerrar	12.34
Rango del día	12.40 - 12.77
Rango de 52 semanas	9.85 - 16.76
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de BNTC

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The com...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Jun 24, 2014

Empleados 19

Bolsa de Valores NasdaqCM

Símbolo bursátil BNTC

Sitio web https://benitec.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Benitec Biopharma fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -37.92M, un aumento de 74.32%.

Estados financieros

Sorpresa de resultados

Benitec Biopharma ha publicado sus resultados trimestrales en May 14, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.24 supera las estimaciones en 0.04, con 0.00% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Benitec Biopharma Inc. publique sus resultados el Sep 22, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

6 meses hace · Simply Wall St.

Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

7 meses hace · Zacks

Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, ...

8 meses hace · Zacks

Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know

The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo...

8 meses hace · Zacks

Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)

Benitec Biopharma (BNTC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...

9 meses hace · Insider Monkey

Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment

Benitec Biopharma Inc. (NASDAQ:BNTC) is one of the best breakout stocks to invest in. On November 4, an analyst at Citizens JMP raised the stock’s price target to $22 from $20 while reiterating an Out...

Página 1 de 2

Benitec Biopharma Inc. (BNTC)